New combo pill for diabetes and hypertension enters early human testing
NCT ID NCT07590466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test a new tablet that combines two common drugs—one for type 2 diabetes and one for high blood pressure—in healthy volunteers. The goal is to see if the single pill works the same in the body as taking the two drugs separately. Thirty-six healthy adults will receive each treatment once in a random order, with blood samples taken to compare drug levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olmesartan medoxomil and Dapagliflozin (fixed-dose combination tablet)
- What this could lead to
- If successful, this could lead to a simpler, single-pill treatment for people with both type 2 diabetes and high blood pressure.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only checks if the combo pill is absorbed similarly, not if it works better or is safer long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?